September 2017 Volume 13, Issue 9

Volume 13, Issue 9 | September 2017

September 2017

In this Issue

Discovery

Drug Discovery News Placeholder Image

Another AI alliance

Exscientia shares artificial intelligence capacity with top pharmaceutical partner
Drug Discovery News Placeholder Image

ReadCoor, WAVE Life Sciences collaborate for research

Partners aim to unlock next-generation stereopure nucleic acid targets with FISSEQ technologies
Drug Discovery News Placeholder Image

‘Building on excellent experiences’

Max Planck Innovation, Daiichi Sankyo and the Lead Discovery Center to pursue cancer lead discovery
Drug Discovery News Placeholder Image

Rare disease research

NIH team identifies cause of muscle disorder CFZS
Drug Discovery News Placeholder Image

Blocking key enzyme may reverse memory loss

MIT study suggests a new approach to developing treatments for Alzheimer’s disease

Research & Development

Drug Discovery News Placeholder Image

Streamlining bispecifics

Merck KGaA uses Genedata functionalities to scale up bispecific antibody discovery programs
Drug Discovery News Placeholder Image

Microsystems with a big impact

Research uses new polymer chip model to grow biomimetic microtissue
Drug Discovery News Placeholder Image

Race in the race against AD

UC Davis awarded more than $14 million for Alzheimer’s disease study in Latinos
Drug Discovery News Placeholder Image

Simplified synthesis

Rice University team details new approach for synthesizing aminating agents
Drug Discovery News Placeholder Image

Lilly and Purdue form strategic research collaboration

Lilly will provide the university up to $52 million to fund life-sciences research over five years

Preclinical

Drug Discovery News Placeholder Image

Inventiva publishes IVA337 data

Results support therapeutic potential of the pan-PPAR agonist for the treatment of NASH
Drug Discovery News Placeholder Image

Good news with NOX

France’s Genkyotex launches GKT831 to target CAFs, delay tumor growth
Drug Discovery News Placeholder Image

Subcutaneous success

Catalyst sees encouraging activity levels in vivo for Factor IX, VIIa products
Drug Discovery News Placeholder Image

Immunovaccine personalizes cancer immunotherapies

DepoVax system successfully combines 14 neoepitope cancer peptides into one formulation
Drug Discovery News Placeholder Image

Progress on ABX464

Compound dampens intestinal inflammation by triggering IL-22 production in activated macrophages

Special Reports

Drug Discovery News Placeholder Image

Special Report on Infectious Disease: The fungus within us

Is our arsenal evolving quickly enough to match its protean foe?

Feature

Drug Discovery News Placeholder Image

Special Focus on CRISPR: CRISPR on the move

Gene-editing technology continues to evolve
Drug Discovery News Placeholder Image

Show Preview: The genome goes to Orlando

ASHG 2017 meeting to showcase the latest on the human genome
Drug Discovery News Placeholder Image

Guest Commentary: Affinity and beyond--Assessing the alternatives to therapeutic antibodies

New technological developments that would benefit from a new breed of affinity binders include antibody-drug conjugates that link cytotoxic drugs to targeting binders, bi-specific affinity molecules that concurrently target multiple biological pathways and new affinity reagents for the evolution of in-vivo imaging. These technologies have the potential to fundamentally reshape the industry, not only offering essential healthcare cost savings, but also to provide new medicines with improved safety and efficacy for patients.
Drug Discovery News Placeholder Image

Patent Docs: Federal Circuit Loosens Requirements for Finding Inequitable Conduct

Earlier this month, the Federal Circuit affirmed a decision by a district court that the patent at issue before it had been obtained through inequitable conduct. However, contrary to prevailing standards the district court used litigation misconduct rather than malfeasance during patent prosecution to justify its decision, raising fears that lawyers involved in obtaining patents for their clients may be found liable for conduct of (other) lawyers representing their clients in litigation.

Editor's Focus

Drug Discovery News Placeholder Image

The treasures in our trove

A look at the bonuses to be found on the DDNews websites with our Editconnect codes

Contract Services

Drug Discovery News Placeholder Image

INC Research propels Catalyst into psychiatric arena

New offering joins existing Oncology and Vaccine networks in the Catalyst suite
Drug Discovery News Placeholder Image

A more vigilant Quanticate

With the thalidomide tragedy still in mind decades later, U.K. CRO heightens pharmacovigilance
Drug Discovery News Placeholder Image

WuXi merges two units

STA Pharmaceutical combines with Pharmaceutical Development Services division

Commentary

Drug Discovery News Placeholder Image

Guest Commentary: De-risking drug development

Can the pharma world better select new molecules that will have a greater than a 1:10,000 chance of progressing through development and making a successful, safe, marketed product?
Drug Discovery News Placeholder Image

Out of order: Significant, but relevant?

There seems to be an assumption that if something is statistically significant, it is medically relevant. The corollary would imply that something determined not statistically significant is therefore not medically relevant. But is this true? And medically relevant for whom?

Clinical Trials

Drug Discovery News Placeholder Image

Going after gonorrhea

Entasis and GARDP partner to develop treatment for increasing threat of resistant gonorrhea
Drug Discovery News Placeholder Image

Dueling with Duchenne

PTC Therapeutics publishes ACT DMD Phase 3 trial data
Drug Discovery News Placeholder Image

An impressive Phase 2 for Reata

Company advances bardoxolone in Alport syndrome based on significant kidney function improvement
Drug Discovery News Placeholder Image

Adding Japan to GALACTIC-HF

Cytokinetics announces positive results for omecamtiv mecarbil in Japanese heart failure patients

Business & Government Policy

Drug Discovery News Placeholder Image

Pairing up against autoimmunity

Eli Lilly and Nektar join forces to seek new treatment for autoimmune conditions
Drug Discovery News Placeholder Image

On the move

Avantor and BioTek expand; labfolder joins Merck Accelerator
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Co-developing tisotumab vedotin for solid tumors

Seattle Genetics exercises option; costs to be split equally with Genmab going forward

Diagnostics

Drug Discovery News Placeholder Image

Biological Dynamics advances exosome isolation technique

ExoVerita lab-on-a-chip system can simplify and streamline the isolation and recovery of exosomes
Drug Discovery News Placeholder Image

Two is better than one

Biodesix’s GeneStrat and VeriStrat tests for non-small cell lung cancer pass with flying colors
Drug Discovery News Placeholder Image

Invitae to acquire CombiMatrix

Combined company hopes to tap power of genetics to inform health decisions when starting a family

Q&A

Drug Discovery News Placeholder Image

Q&A: In-vivo models of infectious disease

We speak to Adriano Flora, associate director of the Scientific Program Management Group at Taconic Biosciences
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue